This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, C.-c.
Right arrow Articles by Yeh, L.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, C.-c.
Right arrow Articles by Yeh, L.-T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2368-2373, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00118-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Absorption, Metabolism, and Excretion of [14C]Viramidine in Humans

Chin-chung Lin,* Christine Xu, Nanqun Zhu, and Li-Tain Yeh

Valeant Research & Development, Costa Mesa, California 92626

Received 27 January 2006/ Returned for modification 24 March 2006/ Accepted 5 May 2006

Absorption, metabolism, and excretion of [14C]viramidine, a prodrug of ribavirin, were studied in humans following a single oral dose (600 mg). Viramidine was rapidly absorbed, with a time to maximum concentration of the drug in plasma of 1.5 h. Viramidine and ribavirin accounted for only 4.3% and 42% of plasma area under the concentration-time curve (AUC) for radioactivity, respectively, indicating extensive conversion of viramidine to ribavirin, followed by further metabolism of ribavirin. The drug was largely trapped in red blood cells (RBC), with an RBC-to-plasma radioactivity AUC0-{infty} ratio of 108. Excretion of total radioactivity in urine and feces accounted for 50.8% and 26.1% of the dose, respectively. The metabolic profile in urine (0 to 24 h) indicated that viramidine was excreted primarily as triazole carboxamide (TCONH2), triazole carboxylic acid nucleoside (TCOOH), and ribavirin with a small amount of unchanged viramidine, which each accounted for 64.1%, 17.0%, 15.7%, and 3.2% of urinary radioactivity, respectively. The amounts of unchanged viramidine (3.4% of dose) and ribavirin (10% of dose) in urine were small after oral administration of viramidine.

* Corresponding author. Mailing address: Valeant Research & Development, 3300 Hyland Avenue, Costa Mesa, CA 92626. Phone: (714) 427-6236, ext. 2062. Fax: (714) 641-7201. E-mail: cclin{at}valeant.com.

Antimicrobial Agents and Chemotherapy, July 2006, p. 2368-2373, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00118-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»